Previous evidence for serum NGAL as a biomarker to detect AKI in patients with liver cirrhosis is mixed due to heterogeneous populations of individual studies and the different diagnostic criteria of AKI used in previous studies. This evidence concerns the gene LCN2 and acute kidney injury.